|
270 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
39 Trials |
|
5519 News |
|
| «12345678910111213...110111» |
- | Trial completion, Phase classification, Enrollment change: CXR01: Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes (clinicaltrials.gov) - Mar 7, 2019
P=N/A, N=204, Completed, Sponsor: University of California, Irvine
Recruiting --> Completed | Phase classification: P2 --> PN/A | N=939 --> 204
- | Trial completion, Metastases: ADVISE: Advanced Methods for Cancer Detection by Vaginal Screening (clinicaltrials.gov) - Mar 6, 2019
P=N/A, N=122, Completed, Sponsor: Anna Tinker
Recruiting --> Completed | Phase classification: P2 --> PN/A | N=939 --> 204 Active, not recruiting --> Completed
- ||| ISA101 / ISA Pharma
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: CervISA: Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer (clinicaltrials.gov) - Mar 6, 2019
P1/2, N=93, Completed, Sponsor: ISA Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Apr 2021 --> Aug 2018 | Trial primary completion date: Apr 2018 --> Aug 2018
- ||| Menopur (menotropin) / Ferring
Trial completion, Trial completion date: A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur® (clinicaltrials.gov) - Mar 5, 2019
P=N/A, N=297, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Apr 2021 --> Aug 2018 | Trial primary completion date: Apr 2018 --> Aug 2018 Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Jun 2018
- || Lovaxin C (axalimogene filolisbac) / Ayala Pharma
Trial completion, Trial completion date, Trial primary completion date: Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer (clinicaltrials.gov) - Mar 5, 2019
P1/2, N=25, Completed, Sponsor: Advaxis, Inc.
Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Jun 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Apr 2017
- | Trial completion, Trial completion date, Oncolytic virus: Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Mar 1, 2019
P1, N=37, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Apr 2017 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Nov 2017
- | Preclinical, Enrollment change, Trial completion date, Trial termination: Use of IMSI in Poor Responders to IVF (clinicaltrials.gov) - Feb 28, 2019
P=N/A, N=10, Terminated, Sponsor: Centro de Infertilidad y Reproducción Humana
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Nov 2017 N=200 --> 10 | Trial completion date: Jul 2018 --> Feb 2019 | Recruiting --> Terminated; DIfficulties with recruitment
- |||| VCL-HB01 / Brickell
Trial completion, Trial completion date: Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine (clinicaltrials.gov) - Feb 27, 2019
P2, N=261, Completed, Sponsor: Vical
N=200 --> 10 | Trial completion date: Jul 2018 --> Feb 2019 | Recruiting --> Terminated; DIfficulties with recruitment Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Dec 2018
- | Trial completion, Preclinical: Antimullerian Hormone Versus Antral Follicle Count for Determination of Gonadotrophin Dosing in IVF (clinicaltrials.gov) - Feb 27, 2019
P=N/A, N=200, Completed, Sponsor: The University of Hong Kong
Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Dec 2018 Recruiting --> Completed
- | cisplatin / Generic mfg.
Enrollment change, Metastases: Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer (clinicaltrials.gov) - Feb 27, 2019
P3, N=374, Recruiting, Sponsor: Korea Cancer Center Hospital
Recruiting --> Completed N=590 --> 374
- | cisplatin / Generic mfg.
Trial completion, Surgery: Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery (clinicaltrials.gov) - Feb 26, 2019
P2, N=106, Completed, Sponsor: Radiation Therapy Oncology Group
N=590 --> 374 Active, not recruiting --> Completed
- | Enrollment change, Trial completion date, Trial initiation date, Trial termination, Trial primary completion date: Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle. (clinicaltrials.gov) - Feb 25, 2019
P4, N=19, Terminated, Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Active, not recruiting --> Completed N=164 --> 19 | Trial completion date: Jun 2019 --> May 2018 | Initiation date: Jun 2018 --> Feb 2017 | Not yet recruiting --> Terminated | Trial primary completion date: Jun 2019 --> May 2018; Difficulties in recruitment
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Screening of Gonococcal and Chlamydial Infections in the Third Trimester (clinicaltrials.gov) - Feb 21, 2019
P=N/A, N=1691, Completed, Sponsor: St. Michael's Hospital, Toronto
N=164 --> 19 | Trial completion date: Jun 2019 --> May 2018 | Initiation date: Jun 2018 --> Feb 2017 | Not yet recruiting --> Terminated | Trial primary completion date: Jun 2019 --> May 2018; Difficulties in recruitment Enrolling by invitation --> Completed | N=1000 --> 1691 | Trial completion date: Nov 2018 --> Feb 2019 | Trial primary completion date: Nov 2018 --> Feb 2019
- | Trial completion, Trial completion date, Trial primary completion date: Safer Sex Program for Young African-American Men (clinicaltrials.gov) - Feb 21, 2019
P2, N=620, Completed, Sponsor: Richard Crosby
Enrolling by invitation --> Completed | N=1000 --> 1691 | Trial completion date: Nov 2018 --> Feb 2019 | Trial primary completion date: Nov 2018 --> Feb 2019 Recruiting --> Completed | Trial completion date: May 2019 --> Apr 2018 | Trial primary completion date: May 2018 --> Nov 2017
- | Trial completion, Metastases: GIVE: Impact of Geriatrician Interventions on Chemotherapy Delivery in Vulnerable Elderly Oncology Patients (clinicaltrials.gov) - Feb 15, 2019
P=N/A, N=233, Completed, Sponsor: Azienda USL 4 Prato
Recruiting --> Completed | Trial completion date: May 2019 --> Apr 2018 | Trial primary completion date: May 2018 --> Nov 2017 Recruiting --> Completed
- || folate-tubulysin (EC1456) / Novartis
Trial completion, Surgery: An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery (clinicaltrials.gov) - Feb 7, 2019
P1, N=3, Completed, Sponsor: Endocyte
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion, Monotherapy, Metastases: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 6, 2019
P3, N=581, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | letrozole / Generic mfg.
Trial completion, Trial completion date: RIOT-B: Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles (clinicaltrials.gov) - Feb 5, 2019
P2/3, N=33, Completed, Sponsor: Sven O. Skouby
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018
- | Trial completion, Trial completion date: Three-dimensional Versus Two-dimensional Ultrasound Guided Embryo Transfer in Women Undergoing ART Treatment (clinicaltrials.gov) - Jan 31, 2019
P=N/A, N=481, Completed, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Sep 2018
- | Enrollment change, Trial completion date, Trial withdrawal: Quantitative MRI for Functional Imaging of the Testis: A New Methodology for Evaluation of the Infertile Male (clinicaltrials.gov) - Jan 30, 2019
P=N/A, N=0, Withdrawn, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Sep 2018 N=20 --> 0 | Trial completion date: Aug 2019 --> Jan 2019 | Enrolling by invitation --> Withdrawn
- | Trial completion, Trial completion date, Trial primary completion date: Hyaluronan-enriched Embryo Transfer Medium for Frozen-thawed Embryo Transfer (clinicaltrials.gov) - Jan 25, 2019
P=N/A, N=550, Completed, Sponsor: The University of Hong Kong
N=20 --> 0 | Trial completion date: Aug 2019 --> Jan 2019 | Enrolling by invitation --> Withdrawn Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Jan 2019 | Trial primary completion date: Jun 2019 --> Jan 2019
- | Trial completion, Trial completion date: Multicenter Italian Validation of EHP-30 (clinicaltrials.gov) - Jan 23, 2019
P=N/A, N=200, Completed, Sponsor: University of Cagliari
Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Jan 2019 | Trial primary completion date: Jun 2019 --> Jan 2019 Recruiting --> Completed | Trial completion date: Oct 2016 --> Nov 2018
- | Enrollment closed: Hyaluronan-enriched Embryo Transfer Medium for Frozen-thawed Embryo Transfer (clinicaltrials.gov) - Jan 23, 2019
P=N/A, N=550, Active, not recruiting, Sponsor: The University of Hong Kong
Recruiting --> Completed | Trial completion date: Oct 2016 --> Nov 2018 Recruiting --> Active, not recruiting
- | Phase classification: Fermented Wheat Germ Extract in Women With Ovarian Cancer (clinicaltrials.gov) - Jan 23, 2019
P1, N=3, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P1
- | metformin / Generic mfg.
Trial completion: Metformin for the Treatment of Endometrial Hyperplasia (clinicaltrials.gov) - Jan 18, 2019
P1, N=18, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed
- | Trial completion: MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer (clinicaltrials.gov) - Jan 17, 2019
P1, N=10, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment closed, Trial completion date, Trial primary completion date: Community-Driven Cervical Cancer Prevention in Western Kenya (clinicaltrials.gov) - Jan 16, 2019
P=N/A, N=7200, Active, not recruiting, Sponsor: Duke University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Feb 2019 | Trial primary completion date: Dec 2018 --> Oct 2016
- || Trial completion date, Trial primary completion date: INREG 1: Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule (clinicaltrials.gov) - Jan 11, 2019
P=N/A, N=20, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Feb 2019 | Trial primary completion date: Dec 2018 --> Oct 2016 Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019
- | Trial completion date, Trial primary completion date: DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings (clinicaltrials.gov) - Jan 7, 2019
P=N/A, N=932, Completed, Sponsor: Children's Oncology Group
Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019 Trial completion date: Mar 2013 --> Aug 2016 | Trial primary completion date: Mar 2013 --> Aug 2016
- | Trial completion, Enrollment change, Trial completion date: Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women (clinicaltrials.gov) - Jan 7, 2019
P=N/A, N=42, Completed, Sponsor: University of Alabama at Birmingham
Trial completion date: Mar 2013 --> Aug 2016 | Trial primary completion date: Mar 2013 --> Aug 2016 Enrolling by invitation --> Completed | N=200 --> 42 | Trial completion date: May 2019 --> Jan 2019
- | Trial completion, Trial completion date, Trial primary completion date, FDG PET: ERRICC: Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy (clinicaltrials.gov) - Jan 7, 2019
P=N/A, N=146, Completed, Sponsor: Hospices Civils de Lyon
Enrolling by invitation --> Completed | N=200 --> 42 | Trial completion date: May 2019 --> Jan 2019 Active, not recruiting --> Completed | Trial completion date: May 2018 --> Aug 2018 | Trial primary completion date: May 2018 --> Aug 2018
- | Clinical protocol, Trial completion, Trial completion date, Trial primary completion date: Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants (clinicaltrials.gov) - Jan 5, 2019
P=N/A, N=581, Completed, Sponsor: University of California, Davis
Active, not recruiting --> Completed | Trial completion date: May 2018 --> Aug 2018 | Trial primary completion date: May 2018 --> Aug 2018 Recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2016 | Trial primary completion date: Dec 2018 --> Mar 2016
- |||| budigalimab (ABBV-181) / AbbVie, tamrintamab pamozirine (SC-003) / AbbVie
Trial completion date, Trial termination, Trial primary completion date, Combination therapy: Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer (clinicaltrials.gov) - Jan 4, 2019
P1a/1b, N=74, Terminated, Sponsor: Stemcentrx
Recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2016 | Trial primary completion date: Dec 2018 --> Mar 2016 Trial completion date: Jan 2020 --> Jan 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2020 --> Jan 2019; Strategic Considerations
- ||| Avastin (bevacizumab) / Roche
Trial completion: BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer (clinicaltrials.gov) - Jan 4, 2019
P=N/A, N=63, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Jan 2020 --> Jan 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2020 --> Jan 2019; Strategic Considerations Active, not recruiting --> Completed
- ||| Trial completion, Trial primary completion date: Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. (clinicaltrials.gov) - Jan 3, 2019
P4, N=116, Completed, Sponsor: LG Life Sciences
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Sep 2017 --> Dec 2017
- buparlisib (AN2025) / Adlai Nortye
Enrollment change, Trial withdrawal, Trial primary completion date, Metastases: BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers (clinicaltrials.gov) - Jan 3, 2019
P2, N=0, Withdrawn, Sponsor: University of Utah
Recruiting --> Completed | Trial primary completion date: Sep 2017 --> Dec 2017 N=54 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2016 --> Jul 2014
- |||| Rubraca (rucaparib) / Pharma& Schweiz
Trial completion, Trial primary completion date, BRCA Biomarker, PARP Biomarker, Metastases: CRUK-PARP/BRCA: Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer (clinicaltrials.gov) - Jan 3, 2019
P2, N=78, Completed, Sponsor: Cancer Research UK
N=54 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2016 --> Jul 2014 Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jan 2015
- ||| varlilumab (CDX 1127) / Celldex
Trial completion: A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers (clinicaltrials.gov) - Jan 3, 2019
P1, N=90, Completed, Sponsor: Celldex Therapeutics
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jan 2015 Active, not recruiting --> Completed
- | veliparib (ABT-888) / AbbVie
New P1/2 trial, Monotherapy, BRCA Biomarker, PARP Biomarker: Veli-BRCA: Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation (clinicaltrials.gov) - Jan 3, 2019
P1/2, N=33, Recruiting, Sponsor: Vejle Hospital
- veliparib (ABT-888) / AbbVie
Enrollment closed, Combination therapy, BRCA Biomarker, PARP Biomarker: Phase II ABT-888 With Cyclophosphamide (clinicaltrials.gov) - Jan 3, 2019
P2, N=29, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- veliparib (ABT-888) / AbbVie
Trial termination, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 3, 2019
P1, N=16, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated
- | Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, veliparib (ABT-888) / AbbVie
Trial completion, Enrollment change, Trial primary completion date, PARP Biomarker, Metastases: Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 3, 2019
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Active, not recruiting --> Completed | N=58 --> 45 | Trial primary completion date: Oct 2016 --> May 2017
- | veliparib (ABT-888) / AbbVie
Trial completion, BRCA Biomarker, PARP Biomarker: Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy (clinicaltrials.gov) - Jan 3, 2019
P1, N=98, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=58 --> 45 | Trial primary completion date: Oct 2016 --> May 2017 Active, not recruiting --> Completed
- veliparib (ABT-888) / AbbVie
Trial completion, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer (clinicaltrials.gov) - Jan 3, 2019
P1, N=107, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion, Trial completion date: Prevalence of Heavy Menstrual Bleeding in Female Population Living in Beijing (clinicaltrials.gov) - Dec 31, 2018
P=N/A, N=2455, Completed, Sponsor: Peking University
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Jul 2015 --> Dec 2016
- | Trial completion, Trial completion date, Trial primary completion date: Intrauterine Injection of Human Chorionic Gonadotropin Injection (hCG) Before Frozen Embryo Transfer on Cycle Outcomes (clinicaltrials.gov) - Dec 28, 2018
P3, N=180, Completed, Sponsor: Royan Institute
Recruiting --> Completed | Trial completion date: Jul 2015 --> Dec 2016 Recruiting --> Completed | Trial completion date: Mar 2017 --> Dec 2018 | Trial primary completion date: Oct 2016 --> Dec 2018
- | Trial completion, Trial completion date, Trial primary completion date: Intrauterine Injection of Human Chorionic Gonadotropin Injection (hCG) Before Embryo Transfer on Pregnancy Outcomes in Frozen Embryo Transfer Cycles. (clinicaltrials.gov) - Dec 28, 2018
P3, N=180, Completed, Sponsor: Royan Institute
Recruiting --> Completed | Trial completion date: Mar 2017 --> Dec 2018 | Trial primary completion date: Oct 2016 --> Dec 2018 Recruiting --> Completed | Trial completion date: Jul 2017 --> Dec 2018 | Trial primary completion date: Jun 2017 --> Dec 2018
- letrozole / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin (clinicaltrials.gov) - Dec 27, 2018
P=N/A, N=9, Completed, Sponsor: University of Kansas
Recruiting --> Completed | Trial completion date: Jul 2017 --> Dec 2018 | Trial primary completion date: Jun 2017 --> Dec 2018 Recruiting --> Completed | N=12 --> 9 | Trial primary completion date: Jun 2015 --> Aug 2014
- | cabergoline / Generic mfg.
Trial completion: Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome (clinicaltrials.gov) - Dec 27, 2018
P2, N=170, Completed, Sponsor: Aljazeera Hospital
Recruiting --> Completed | N=12 --> 9 | Trial primary completion date: Jun 2015 --> Aug 2014 Recruiting --> Completed
- | Trial completion: Robot Assisted Laparoscopic Hysterectomy vs. Abdominal Hysterectomy in Endometrial Cancer (clinicaltrials.gov) - Dec 26, 2018
P=N/A, N=50, Completed, Sponsor: University Hospital, Linkoeping
Recruiting --> Completed Recruiting --> Completed